source
- FDA invites stakeholder input to shape a new Quantitative Medicine Innovation NetworkThe FDA announced it is looking for feedback from a broad range of stakeholders to help design a Quantitative Medicine Innovation Network (QMIN). The proposed QMIN would be a cross-sector platform…
- Amgen drops early-stage obesity drug candidate AMG-513Amgen announced it is discontinuing its early-stage obesity candidate AMG-513. The program was in Phase 1, but the company provided no details about the study or the reasons for the halt. A spokes…